Renal Cell Carcinoma with Chromosome 6p Amplification Including the TFEB Gene

A Novel Mechanism of Tumor Pathogenesis?

Sean R. Williamson, David Grignon, Liang Cheng, Laura Favazza, Dibson D. Gondim, Shannon Carskadon, Nilesh S. Gupta, Dhananjay A. Chitale, Shanker Kalyana-Sundaram, Nallasivam Palanisamy

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Amplification of chromosome 6p has been implicated in aggressive behavior in several cancers, but has not been characterized in renal cell carcinoma (RCC). We identified 9 renal tumors with amplification of chromosome 6p including the TFEB gene, 3 by fluorescence in situ hybridization, and 6 from the Cancer Genome Atlas (TCGA) databases. Patients' ages were 28 to 78 years (median, 61 y). Most tumors were high stage (7/9 pT3a, 2/9 pN1). Using immunohistochemistry, 2/4 were positive for melanocytic markers and cathepsin K. Novel TFEB fusions were reported by TCGA in 2; however, due to a small composition of fusion transcripts compared with full-length transcripts (0.5/174 and 3.3/132 FPKM), we hypothesize that these represent secondary fusions due to amplification. Five specimens (4 TCGA, 1 fluorescence in situ hybridization) had concurrent chromosome 3p copy number loss or VHL deletion. However, these did not resemble clear cell RCC, had negative carbonic anhydrase IX labeling, lacked VHL mutation, and had papillary or unclassified histology (2/4 had gain of chromosome 7 or 17). One tumor each had somatic FH mutation and SMARCB1 mutation. Chromosome 6p amplification including TFEB is a previously unrecognized cytogenetic alteration in RCC, associated with heterogenous tubulopapillary eosinophilic and clear cell histology. The combined constellation of features does not fit cleanly into an existing tumor category (unclassified), most closely resembling papillary or translocation RCC. The tendency for high tumor stage, varied tubulopapillary morphology, and a subset with melanocytic marker positivity suggests the possibility of a unique tumor type, despite some variation in appearance and genetics.

Original languageEnglish (US)
Pages (from-to)287-298
Number of pages12
JournalAmerican Journal of Surgical Pathology
Volume41
Issue number3
DOIs
StatePublished - 2017

Fingerprint

Renal Cell Carcinoma
Chromosomes
Genes
Neoplasms
Atlases
Genome
Fluorescence In Situ Hybridization
Mutation
Histology
Cathepsin K
Chromosomes, Human, Pair 17
Chromosomes, Human, Pair 7
Cytogenetics
Immunohistochemistry
Databases
Kidney

Keywords

  • chromosome 6p
  • kidney cancer
  • renal cell carcinoma
  • TFEB gene
  • tumor classification

ASJC Scopus subject areas

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine

Cite this

Renal Cell Carcinoma with Chromosome 6p Amplification Including the TFEB Gene : A Novel Mechanism of Tumor Pathogenesis? / Williamson, Sean R.; Grignon, David; Cheng, Liang; Favazza, Laura; Gondim, Dibson D.; Carskadon, Shannon; Gupta, Nilesh S.; Chitale, Dhananjay A.; Kalyana-Sundaram, Shanker; Palanisamy, Nallasivam.

In: American Journal of Surgical Pathology, Vol. 41, No. 3, 2017, p. 287-298.

Research output: Contribution to journalArticle

Williamson, SR, Grignon, D, Cheng, L, Favazza, L, Gondim, DD, Carskadon, S, Gupta, NS, Chitale, DA, Kalyana-Sundaram, S & Palanisamy, N 2017, 'Renal Cell Carcinoma with Chromosome 6p Amplification Including the TFEB Gene: A Novel Mechanism of Tumor Pathogenesis?', American Journal of Surgical Pathology, vol. 41, no. 3, pp. 287-298. https://doi.org/10.1097/PAS.0000000000000776
Williamson, Sean R. ; Grignon, David ; Cheng, Liang ; Favazza, Laura ; Gondim, Dibson D. ; Carskadon, Shannon ; Gupta, Nilesh S. ; Chitale, Dhananjay A. ; Kalyana-Sundaram, Shanker ; Palanisamy, Nallasivam. / Renal Cell Carcinoma with Chromosome 6p Amplification Including the TFEB Gene : A Novel Mechanism of Tumor Pathogenesis?. In: American Journal of Surgical Pathology. 2017 ; Vol. 41, No. 3. pp. 287-298.
@article{b2be646ce14c4a0ea8a21aaf32a7bdea,
title = "Renal Cell Carcinoma with Chromosome 6p Amplification Including the TFEB Gene: A Novel Mechanism of Tumor Pathogenesis?",
abstract = "Amplification of chromosome 6p has been implicated in aggressive behavior in several cancers, but has not been characterized in renal cell carcinoma (RCC). We identified 9 renal tumors with amplification of chromosome 6p including the TFEB gene, 3 by fluorescence in situ hybridization, and 6 from the Cancer Genome Atlas (TCGA) databases. Patients' ages were 28 to 78 years (median, 61 y). Most tumors were high stage (7/9 pT3a, 2/9 pN1). Using immunohistochemistry, 2/4 were positive for melanocytic markers and cathepsin K. Novel TFEB fusions were reported by TCGA in 2; however, due to a small composition of fusion transcripts compared with full-length transcripts (0.5/174 and 3.3/132 FPKM), we hypothesize that these represent secondary fusions due to amplification. Five specimens (4 TCGA, 1 fluorescence in situ hybridization) had concurrent chromosome 3p copy number loss or VHL deletion. However, these did not resemble clear cell RCC, had negative carbonic anhydrase IX labeling, lacked VHL mutation, and had papillary or unclassified histology (2/4 had gain of chromosome 7 or 17). One tumor each had somatic FH mutation and SMARCB1 mutation. Chromosome 6p amplification including TFEB is a previously unrecognized cytogenetic alteration in RCC, associated with heterogenous tubulopapillary eosinophilic and clear cell histology. The combined constellation of features does not fit cleanly into an existing tumor category (unclassified), most closely resembling papillary or translocation RCC. The tendency for high tumor stage, varied tubulopapillary morphology, and a subset with melanocytic marker positivity suggests the possibility of a unique tumor type, despite some variation in appearance and genetics.",
keywords = "chromosome 6p, kidney cancer, renal cell carcinoma, TFEB gene, tumor classification",
author = "Williamson, {Sean R.} and David Grignon and Liang Cheng and Laura Favazza and Gondim, {Dibson D.} and Shannon Carskadon and Gupta, {Nilesh S.} and Chitale, {Dhananjay A.} and Shanker Kalyana-Sundaram and Nallasivam Palanisamy",
year = "2017",
doi = "10.1097/PAS.0000000000000776",
language = "English (US)",
volume = "41",
pages = "287--298",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Renal Cell Carcinoma with Chromosome 6p Amplification Including the TFEB Gene

T2 - A Novel Mechanism of Tumor Pathogenesis?

AU - Williamson, Sean R.

AU - Grignon, David

AU - Cheng, Liang

AU - Favazza, Laura

AU - Gondim, Dibson D.

AU - Carskadon, Shannon

AU - Gupta, Nilesh S.

AU - Chitale, Dhananjay A.

AU - Kalyana-Sundaram, Shanker

AU - Palanisamy, Nallasivam

PY - 2017

Y1 - 2017

N2 - Amplification of chromosome 6p has been implicated in aggressive behavior in several cancers, but has not been characterized in renal cell carcinoma (RCC). We identified 9 renal tumors with amplification of chromosome 6p including the TFEB gene, 3 by fluorescence in situ hybridization, and 6 from the Cancer Genome Atlas (TCGA) databases. Patients' ages were 28 to 78 years (median, 61 y). Most tumors were high stage (7/9 pT3a, 2/9 pN1). Using immunohistochemistry, 2/4 were positive for melanocytic markers and cathepsin K. Novel TFEB fusions were reported by TCGA in 2; however, due to a small composition of fusion transcripts compared with full-length transcripts (0.5/174 and 3.3/132 FPKM), we hypothesize that these represent secondary fusions due to amplification. Five specimens (4 TCGA, 1 fluorescence in situ hybridization) had concurrent chromosome 3p copy number loss or VHL deletion. However, these did not resemble clear cell RCC, had negative carbonic anhydrase IX labeling, lacked VHL mutation, and had papillary or unclassified histology (2/4 had gain of chromosome 7 or 17). One tumor each had somatic FH mutation and SMARCB1 mutation. Chromosome 6p amplification including TFEB is a previously unrecognized cytogenetic alteration in RCC, associated with heterogenous tubulopapillary eosinophilic and clear cell histology. The combined constellation of features does not fit cleanly into an existing tumor category (unclassified), most closely resembling papillary or translocation RCC. The tendency for high tumor stage, varied tubulopapillary morphology, and a subset with melanocytic marker positivity suggests the possibility of a unique tumor type, despite some variation in appearance and genetics.

AB - Amplification of chromosome 6p has been implicated in aggressive behavior in several cancers, but has not been characterized in renal cell carcinoma (RCC). We identified 9 renal tumors with amplification of chromosome 6p including the TFEB gene, 3 by fluorescence in situ hybridization, and 6 from the Cancer Genome Atlas (TCGA) databases. Patients' ages were 28 to 78 years (median, 61 y). Most tumors were high stage (7/9 pT3a, 2/9 pN1). Using immunohistochemistry, 2/4 were positive for melanocytic markers and cathepsin K. Novel TFEB fusions were reported by TCGA in 2; however, due to a small composition of fusion transcripts compared with full-length transcripts (0.5/174 and 3.3/132 FPKM), we hypothesize that these represent secondary fusions due to amplification. Five specimens (4 TCGA, 1 fluorescence in situ hybridization) had concurrent chromosome 3p copy number loss or VHL deletion. However, these did not resemble clear cell RCC, had negative carbonic anhydrase IX labeling, lacked VHL mutation, and had papillary or unclassified histology (2/4 had gain of chromosome 7 or 17). One tumor each had somatic FH mutation and SMARCB1 mutation. Chromosome 6p amplification including TFEB is a previously unrecognized cytogenetic alteration in RCC, associated with heterogenous tubulopapillary eosinophilic and clear cell histology. The combined constellation of features does not fit cleanly into an existing tumor category (unclassified), most closely resembling papillary or translocation RCC. The tendency for high tumor stage, varied tubulopapillary morphology, and a subset with melanocytic marker positivity suggests the possibility of a unique tumor type, despite some variation in appearance and genetics.

KW - chromosome 6p

KW - kidney cancer

KW - renal cell carcinoma

KW - TFEB gene

KW - tumor classification

UR - http://www.scopus.com/inward/record.url?scp=85007205638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007205638&partnerID=8YFLogxK

U2 - 10.1097/PAS.0000000000000776

DO - 10.1097/PAS.0000000000000776

M3 - Article

VL - 41

SP - 287

EP - 298

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 3

ER -